Jinjian LU 陸金健

• Outstanding Reviewer Award, China Association for Science and Technology (2022)
• CNPHARS Annual Young Pharmacologists Award (2016)
• Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2014)
• Member of 2nd Prize of Natural Science: Macao Science and Technology Awards (2012)

• Journal Contributions

Please click here for the full publications

https://www.researchgate.net/profile/Jin-Jian_Lu

https://scholar.google.com/citations?user=G7DwcegAAAAJ&hl=en

Representative publications in recent years (*Corresponding or co-corresponding author)

1. Ye ZH, Yu WB, Huang MY, Chen YY, Zhang LL, Leung CH, Zhang XL, Tang Z, Li T, Lu JJ*. Repurposing cardiac glycosides to potentiate CD47 blockade through calreticulin-mediated phagocytic effects for lung cancer treatment. Advanced Science. 2025, e08245.
2. Huang MY, Xu CC, Chen Q, Zhang YM, Lyu WY, Ye ZH, Li T*, Huang MQ*, Lu JJ*. Ginsenoside Rh2 in combination with IFNγ potentiated the anti-cancer effect by enhancing interferon signaling response in colorectal cancer cells. Acta Pharmacologica Sinica. 2025, 46(9): 2534-46.
3. Yu WB, Ye ZH, Shi JJ, Deng WQ, Chen J, Lu JJ*. Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells. Biochemical Pharmacology. 2025, 236: 116898.
4. Lyu WY, Cao J, Deng WQ, Huang MY, Guo H, Li T*, Lin LG*, Lu JJ*. Xerophenone H, a naturally-derived proteasome inhibitor, triggers apoptosis and paraptosis in lung cancer. Phytomedicine. 2025, 141: 156647.
5. Deng WQ, Ye ZH, Tang Z, Zhang XL, Lu JJ*. Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases. Acta Pharmaceutica Sinica B. 2025, 15(2): 757-91.
6. Li T*, Huang M, Lu JJ*. Cancer statistics and trends in China: the potential of natural product application. Chinese Journal of Natural Medicines. 2024, 22(8): 673-5.
7. Xu CC, Lin YF, Huang MY, Zhang XL, Wang P, Huang MQ*, Lu JJ*. Paraptosis: a non-classical paradigm of cell death for cancer therapy. Acta Pharmacologica Sinica. 2024, 45(2): 223-37.
8. Huang MY, Chen YC, Lyu WY, He XY, Ye ZH, Huang CY, He XL, Chen X, Chen X, Zhang B, Kai G, Zhang X, Li T*, Huang M*, Lu JJ*. Ginsenoside Rh2 augmented anti-PD-L1 immunotherapy by reinvigorating CD8+ T cells via increasing intratumoral CXCL10. Pharmacological Research. 2023, 106988.
9. Ye ZH, Yu WB, Huang MY, Chen J, Lu JJ*. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives. Acta Pharmaceutica Sinica B. 2023, 13(4): 1467-87.
10. Yu WB, Chen YC, Huang CY, Ye ZH, Shi W, Zhu H, Shi JJ, Chen J, Lu JJ*. CD47 blockade improves the therapeutic effect of osimertinib in non-small cell lung cancer. Frontiers of Medicine. 2023, 17(1): 105-18.
11. Xu YL, Yuan LW, Jiang XM, Su MX, Huang MY, Chen YC, Zhang LL, Chen X, Zhu H, Lu JJ*. Glutathione peroxidase 8 expression on cancer cells and cancer-associated fibroblasts facilitates lung cancer metastasis. MedComm. 2022, 3(3): e152.
12. Chen YC, HE XL, Qi L, Shi W, Yuan LW, Huang MY, Xu YL, Chen X, Gu L, Zhang LL, Lu JJ*. Myricetin inhibits interferon-γ-induced PD-L1 and IDO1 expression in lung cancer cells. Biochemical Pharmacology. 2022, 197: 114940.
13. Su MX, Xu YL, Jiang XM, Huang MY, Zhang LL, Yuan LW, Xu XH, Zhu Q, Gao JL, Lu JH, Chen X, Huang MQ, Wang Y, Lu JJ*. c-MYC-mediated TRIB3/P62⁺ aggresomes accumulation triggers paraptosis upon the combination of everolimus and ginsenoside Rh2. Acta Pharmaceutica Sinica B. 2022, 12(3): 1240-53.
14. Huang MY, Jiang XM, Wang BL, Sun Y, Lu JJ*. Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacology & Therapeutics. 2021, 219: 107694.
15. Ye ZH, Jiang XM, Huang MY, Xu YL, Chen YC, Yuan LW, Huang CY, Yu WB, Chen X, Lu JJ*. Regulation of CD47 expression by interferon-gamma in cancer cells. Translational Oncology. 2021, 14: 101162.
16. Yuan LW, Jiang XM, Xu YL, Huang MY, Chen YC, Yu WB, Su MX, Ye ZH, Chen X, Wang Y, Lu JJ*. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Phytomedicine. 2021, 80: 153394.
17. Yu WB, Ye ZH, Chen X, Shi JJ*, Lu JJ*. The development of small-molecule inhibitors targeting CD47. Drug Discovery Today, 2021, 26(2): 561-68.
18. Jiang XM, Xu YL, Yuan LW, Zhang LL, Huang MY, Ye ZH, Su MX, Chen X, Zhu H, Ye R, Lu JJ*. TGFβ2-mediated epithelial-mesenchymal transition and NF-κB pathway activation contribute to osimertinib resistance. Acta Pharmacologica Sinica. 2021, 42: 451-9.
19. Li T, Xu XH, Guo X, Yuan T, Tang ZH, Jiang XM, Xu YL, Zhang LL, Chen X, Zhu H, Shi JJ, Lu JJ*. Activation of Notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus. Biochemical Pharmacology. 2020, 175: 113921.
20. Zhang LL, Guo J, Jiang XM, Chen X, Wang Y, Li A, Lin LG*, Li H*, Lu JJ*. Identification of nagilactone E as a protein synthesis inhibitor with anticancer activity. Acta Pharmacologica Sinica. 2020, 41: 698-705.

• Book Chapter

 – Pharmacology. China Science Publishing & Media LTD. ISBN: 978-7-03-075287-1. August 2023.

 – Essay Writing in Pharmacy and Pharmaceutical Science. People’s Medical Publishing House Co. LTD. ISBN: 978-7-117-29706-6. January

 – Pharmacology in Chinese medicines (3^rd Edition). Shanghai Scientific & Technical Publishers. ISBN: 978-7-5478-4239-3/R·1738. January 2019.

 – Advances of Chinese medicines for cancer therapy. People’s Medical Publishing House Co. LTD. ISBN: 978-7-117-16227-2/R·16228. October, 2012.

Editorial Board Member

• Chinese Medicine (Associate Editor & Director of the Editorial Office)
• Chinese Journal of Natural Medicines (Handling Editor)
• Translational Oncology
• Anti-Cancer Agents in Medicinal Chemistry
• Current Molecular Pharmacology
• Clinical Traditional Medicine and Pharmacology
• Pharmacological Research – Modern Chinese Medicine

Peer Reviewer (Project)

• National Natural Science Foundation of China
• French National Research Agency
• Poland National Science Center
• Health and Medical Research Fund, Hong Kong SAR

Peer Reviewer (Journal)

As a reviewer for 100+ scientific journals, Prof. Lu won the honors of outstanding reviewer in multiple journals, such as Acta Pharmacologica Sinica, Chinese Journal of Natural Medicines, European Journal of Pharmacology, Journal of Ethnopharmacology, Phytomedicine, etc.